Stock Research for ORMP


Featured Broker: Ally Invest

Get the due diligence for another stock.


ORMP Stock Chart & Research Data

The ORMP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ORMP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ORMP Due diligence Resources & Stock Charts

The ORMP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ORMP Detailed Price Forecast - CNN Money CNN View ORMP Detailed Summary - Google Finance
Yahoo View ORMP Detailed Summary - Yahoo! Finance Zacks View ORMP Stock Research & Analysis -

Stock Analysis

TradeIdeas View ORMP Trends & Analysis - Trade-Ideas Barrons View ORMP Major Holders - Barrons
NASDAQ View ORMP Call Transcripts - NASDAQ Seeking View ORMP Breaking News & Analysis - Seeking Alpha
Spotlight View ORMP Annual Report - OTC Report View ORMP OTC Short Report -
TradeKing View ORMP Fundamentals - TradeKing Charts View ORMP SEC Filings - Bar Chart
WSJ View Historical Prices for ORMP - The WSJ Morningstar View Performance/Total Return for ORMP - Morningstar
MarketWatch View the Analyst Estimates for ORMP - MarketWatch CNBC View the Earnings History for ORMP - CNBC
StockMarketWatch View the ORMP Earnings - StockMarketWatch MacroAxis View ORMP Buy or Sell Recommendations - MacroAxis
Bullish View the ORMP Bullish Patterns - American Bulls Short Pains View ORMP Short Pain Metrics -

Social Media Mentions

StockTwits View ORMP Stock Mentions - StockTwits PennyStocks View ORMP Stock Mentions - PennyStockTweets
Twitter View ORMP Stock Mentions - Twitter Invest Hub View ORMP Investment Forum News - Investor Hub
Yahoo View ORMP Stock Mentions - Yahoo! Message Board Seeking Alpha View ORMP Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ORMP - Insider Cow View Insider Transactions for ORMP - Insider Cow
CNBC View ORMP Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ORMP - OTC Markets
Yahoo View Insider Transactions for ORMP - Yahoo! Finance NASDAQ View Institutional Holdings for ORMP - NASDAQ

Stock Charts

FinViz View ORMP Stock Insight & Charts - StockCharts View ORMP Investment Charts -
BarChart View ORMP Stock Overview & Charts - BarChart Trading View View ORMP User Generated Charts - Trading View

Latest Financial News for ORMP

Oramed Pharmaceuticals' CEO Letter to Shareholders
Posted on Tuesday January 15, 2019

JERUSALEM , Jan. 15, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( ) Dear Shareholders, We opened the year 2019 with the announcement of our receipt of a ...

Oramed Receives Additional $3 Million Milestone Payment from HTIT
Posted on Wednesday January 09, 2019

JERUSALEM, Jan. 9, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (, a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received a milestone payment of $3 million from Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT). This milestone is part of a previously-announced license and investment agreement between Oramed and HTIT. "China is currently the largest single diabetes population in the world," stated Oramed CEO Nadav Kidron.

ORMP: Two Studies Ongoing for ORMD-0801 with Data Readouts in 2019…
Posted on Monday December 17, 2018

In Nov. 2018, Oramed Pharmaceuticals Inc. (ORMP) filed form 10-K with financial results for fiscal year 2018 that ended Aug. 31, 2018. The company reported revenues of $2.449 million, which was very similar to the $2.456 million reported in fiscal year 2017. Cost of revenues in fiscal year 2018 decreased to income of $86,000 compared to cost of $187,000 in fiscal year 2017.

Is Oramed Pharmaceuticals Inc’s (NASDAQ:ORMP) CEO Paid Enough Relative To Peers?
Posted on Tuesday November 27, 2018

Nadav Kidron has been the CEO of Oramed Pharmaceuticals Inc (NASDAQ:ORMP) since 2006. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth

Stock Market & Investing Books

Enter a stock symbol to view the stock details.